fMRI decoded neurofeedback being tested for therapy to reduce PTSD, phobias

Jodelle Maglaya | | Health Imaging | Screening

Scientists at the ATR Computational Neuroscience Lab in Japan are using a new technique, called fMRI decoded neurofeedback (DecNef) in hopes to treat patients suffering from post-traumatic stress disorder (PTSD) and phobias. 

Data suggests that this approach is somewhat promising because it has helped patients in reducing anxieties triggered by specific memories, without asking them to think about them conciously. 

Lead researcher Mitsuo Kawato hopes that this study will become another way to treat patients. Exposure therapy accounts for a 40 percent drop-out rate amongst PTSD patients.

View full article: 

https://www.theguardian.com/science/2016/nov/21/tests-raise-hopes-for-radical-n…

Jodelle Maglaya

Jodelle joined TriMed Media Group in 2016 as a senior writer, focusing on content for Radiology Business and Health Imaging. After receiving her master's from DePaul University, she worked as a news reporter and communications specialist.

Related Content

AI reduces CT lung cancer screening workload by nearly 80%
Abbreviated MRI protocols present suitable alternatives for liver cancer screening
Routine abdominal CTs offer insight into cardiovascular risk
Screening efforts have helped avert millions of cancer-related deaths in recent decades
What breast density status can tell us about cardiovascular risk
FDA clears AI tool that flags signs of heart disease in chest CT scans

Around the web

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
‘A significant milestone’: First US patients receive doses of new PET radiotracer for CAD

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care. 

Cardiovascular Business
Continuation of 99mTc-PYP shortage prompts need for alternative cardiac amyloidosis imaging

After three years of intermittent shortages of nuclear imaging tracer technetium-99m pyrophosphate, there are no signs of the shortage abating.